Connect with us

International

The Cold Truth about COVID-19 Vaccines

Demand for vaccine storage freezers, three companies told GEN, extends beyond traditional customers such as biopharmas and academic labs to include healthcare providers and pharmacies, many of which require support as they navigate the unfamiliar territor

Published

on

Leslie B. Vosshall, PhD, a neuroscientist at the Rockefeller University and a Howard Hughes Medical Institute investigator

Eighteen months ago, Leslie B. Vosshall, PhD, a leading neuroscientist at the Rockefeller University and a Howard Hughes Medical Institute investigator, took to Twitter to voice her frustrations with a mundane yet critical piece of lab equipment.

“Does anybody make a RELIABLE freezer for scientists?” she pleaded, after trashing her existing malfunctioning equipment. Vosshall’s timeline briefly turned into a Consumer Reports column on lab equipment, as researchers echoed her sentiments while endorsing products, notably from Stirling Ultra and Panasonic.

Vosshall recently reiterated her recommendations as the topic of reliable ultra-cold storage solutions suddenly became headline news. With the first COVID-19 vaccines due to reach patients in a matter of weeks—including some that require cold storage down to -80º C (-112º F)—companies that manufacture freezers are scrambling to keep up with surging customer demand.

The demand led Stirling Ultracold this year to expand its staff by 30%, to roughly 150 people, while business has grown about 150% from the first quarter to the current quarter, CEO Dusty Tenney told GEN. Plans to introduce several new products this year have been shelved as COVID-19 refocused priorities. Stirling Ultracold has shifted its business entirely toward serving customers scrambling to procure its freezers.

Dusty Tenney, Stirling Ultracold CEO

“We put a lot of our development on hold. We understand the importance of this mission globally, to really help and support the world in its mission to get past this pandemic,” Tenney said. “This mission is way too important for us, at least in the short term.”

Stirling Ultracold markets three ultra-low temperature freezers: the upright SU780XLE, the portable ULT25NEU, and the undercounter SU105UE, at prices ranging from $7,000 to $15,000.

Among Stirling Ultracold’s customers is Infinity BiologiX (IBX), a Piscataway, NJ-based central lab that maintains one of the world’s largest academic biorepositories and also serves researchers with biological sample processing and cell line services.

“We’re trying to take the headache away from the end users,” said Robin Grimwood, IBX’s president and COO. “The freezer farms can hold bulk vaccine storage. Then we come as the next step, where we’re holding it locally for our clients, and then helping them with the distribution strategy.”

IBX’s COVID testing site is one of the largest in the New York area. In choosing freezers, Grimwood said, IBX considers power consumption, heat load, storage capacity, noise, and especially reliability: “You don’t want your freezers to be going wrong. But if they do go wrong, you’ve got a limited time to get the samples from one freezer into the next freezer before the samples degrade.”

Grimwood said IBX’s range of cold storage environments attracted one recent customer, New York-Presbyterian Hospital, as it prepares for the arrival of COVID-19 vaccines: “They obviously know that they need to be prepared. They have been told to prepare. But they don’t know what to prepare for.”

Storage requirements

A Stirling Ultracold employee inspects one of the company’s ultra-low temperature freezers. [Stirling Ultracold]
Currently, there are no recommended storage guidance or standards for ultra-low temperature vaccine handling. Each leading COVID-19 vaccine comes with different storage requirements. Messenger RNA (mRNA) vaccines are particularly vulnerable to degradation by enzymes, hence vaccine developers modify their mRNAs to enhance stability, contain the mRNA in lipid nanoparticles—differences between which can explain why some vaccines require colder storage than others—and ultimately freeze the mRNA.

Two leading COVID-19 vaccine candidates poised for release are mRNA-based. Pfizer and BioNTech’s BNT162b2, the leading candidate in the companies’ BNT162 vaccine program, requires shipping and storage at -70º C. Pfizer and BioNTech—which on Friday requested authorization of BNT162b2 for emergency use—say they have developed temperature-controlled thermal shippers using dry ice to maintain temperature conditions of between -70º C and +10º C.

The shippers can be used as temporary storage units for 15 days by refilling with dry ice. Once thawed, the vaccine can be refrigerated for five days. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.

By contrast, Moderna says its mRNA-based vaccine mRNA-1273—which showed 94.5% effectiveness in early Phase III data—“must be stored at 2º to 8º C in a secure area with limited access (unblinded personnel only) and protected from moisture and light until it is prepared for administration,” according to the protocol for its 30,000+ patient Phase III COVE trial (NCT04470427).

Moderna recently announced a longer shelf life for mRNA-1273, saying the vaccine remained stable at 2º to 8º C for 30 days (up from an earlier estimate of just seven days). Moderna added that mRNA-1273 remains stable at -20º C for up to six months, “and at room temperature for up to 12 hours.”

AstraZeneca’s vaccine candidate AZD1222, which is being co-developed with the University of Oxford and a spinout, also allows for storage and shipping at -20º C. AstraZeneca said today that AZD1222 generated positive Phase III efficacy ranging from 62% when given to 2,741 participants as two full doses at least one month apart—to 90% when given to 8,895 participants as a half dose, followed by a full dose at least one month apart. A total of 131 COVID-19 cases were reported in the interim analysis.

Novavax’s NVX-CoV2373 requires shipping and storage at 2º to 8º C.

“We expect the product to be viable a minimum of six months at 2º to 8º C, and at least 24 hours at room temperature,” Novavax spokesperson Edna Kaplan said. Novavax plans to distribute NVX-CoV2373 in multidose vials, with each vial containing ten doses. “The vaccine is ready-to-use and does not require admixing or reconstitution. It can be delivered using any standard needle and syringe, including those routinely used in vaccination programs,” she said.

Speaking at the virtual HLTH 2020 conference in October, FDA Commissioner Stephen M. Hahn, MD, said cold storage requirements will not be a deciding factor as his agency decides on approvals for COVID-19 vaccine candidates. However, Hahn said that cold chain requirements will be evaluated when it is shown to affect the safety or effectiveness of those vaccines.

Getting warmer

Translate Bio, which is developing MRT5500 through an up-to-$2.3 billion collaboration with Sanofi, said its mRNA-based COVID-19 vaccine originally required storage at -80º C.

Frank DeRosa, PhD, Translate Bio’s chief technology officer.

“We already have generated data and formulations showing stability at -20º C and we hope to implement this for an anticipated Phase III trial for MRT5500,” said Frank DeRosa, PhD, Translate Bio’s chief technology officer.

“We have been working diligently on formulations that would allow for storage and transport at higher temperatures for longer amounts of times,” DeRosa said. “This will be a critical component of distributing our vaccine at a large-scale level, and we are committed to working with Sanofi, experts in global vaccine distribution, on this important issue. Sanofi will be responsible for distribution and they have the global infrastructure in place to manage this process.”

In the longer term, Translate Bio hopes to apply to its COVID-19 program a lyophilized formulation that would allow for extended refrigeration at 2º to 8º C. That formulation has generated encouraging stability data in other pipeline programs.

Non-RNA vaccines, as with therapeutics, do not require ultra-low temperatures. Janssen Pharmaceutical Cos. says its JNJ-78436735, an adenovirus vaccine based on the company’s using Janssen’s AdVac® and PER.C6® vaccine technology platforms, can be stored at standard refrigerator temperatures.

“We currently expect to store then transport our vaccine to customer warehouses at 2º to 8º C, based on available stability data using this vaccine platform,” said Craig Stoltz, a spokesman for Janssen Manufacturing & Technical Operations. “We will use the same cold chain technologies we use today to transport treatments for cancer, immunological disorders, and other medicines. We anticipate our vaccine candidate to be compatible with standard distribution channels without the need for new distribution infrastructure,” Stoltz added.

Sanofi is also partnering with GlaxoSmithKline (GSK) on another COVID-19 vaccine in development, a vaccine incorporating Sanofi’s S-protein COVID-19 antigen, which is based on recombinant DNA technology; and GSK’s pandemic AS03 adjuvant. That vaccine can be stored at 2º to 8º C.

However, Russia’s approved COVID-19 vaccine Sputnik V, developed by the Gamaleya Research Institute of Epidemiology and Microbiology, requires storage at -20º C (-4º F). Sputnik V consisting of two components, administered 21 days apart: A recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene, and a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.

Faster timeline, more customers

The scale and level of collaboration required to develop and ramp up distribution of COVID-19 vaccines from production to distribution to point of care injection is unprecedented, said Alex Esmon, PhD, senior director and general manager for the strategic business segment, that includes ultra-low temperature freezers at Thermo Fisher Scientific: “The industry has been making progress with mRNA-based vaccines, but the COVID-19 pandemic has dramatically accelerated the timeline.”

Thermo Fisher Scientific markets 198 freezers of varying sizes and temperatures, the coldest ones operating as low as -86º C. The company’s three largest freezers have capacities of 33.5 cu. ft. (949 L) and 700 2-inch cryoboxes, but only one operates on U.S. voltage of 115 volts—the TSX70086A, which sells for almost $30,000.

According to Esmon, Thermo is increasing production of ultra-low temperature freezers, -20º C freezers and refrigerators “to manage demand and ensure availability and we’re confident we have the capacity to meet the needs of our customers.”

The cold-storage requirements of leading COVID-19 vaccines is changing the types of customers reaching out to freezer manufacturers.

“It’s a multifaceted increase in demand. I’d say the big drivers have been smaller clinics, state health, as well as logistic and shipping companies,” said Carl Radosevich, senior manager, scientific applications & collaborations with PHC Corp. of North America. PHC is the former biomedical division of Panasonic Healthcare, which markets freezers for life sciences uses under the PhCbi brand.

“The demand has certainly increased especially for -80º C freezers,” Radosevich said. “The last three months, especially once the various state health departments started submitting their vaccine preparation plans, that’s where we really started to see this demand.”

Hospitals have also expanded their freezer demand, as smaller facilities may not have previously needed -80º C units. Larger hospitals need freezers beyond those in diagnostic or research lab settings, including sites where vaccines will be administered.

“Some customers to which we were selling high volumes of vaccine storage refrigerators now need minus 80s [freezers]… We’ve had to try to understand where the vaccines are going, so we can advise correctly as to which unit they need to store those vaccines,” Radosevich added.

PHC markets its PHCbi-branded, -86º C ultra-low temperature freezers based on two types of refrigeration systems. The company’s flagship PHCbi VIP ECO Series, which operates on natural refrigerants, offers five models in three sizes from 18.6 cu. ft. (528L) to 29.8 cu. ft (845 L). The PHCbi TwinGuard Series, which uses two independent refrigeration systems, offers a 25.7 cu. ft. (729 L) chest freezer and three upright freezers, the largest being 25.3 cu. ft. (715 L).

Toughest challenges

Esmon of Thermo Fisher Scientific identified the toughest challenges associated with COVID-19 vaccines. One is managing temperature throughout their distribution, achievable with temperature tracking devices and digital solutions. This is especially critical for mRNA vaccines, for which temperature maintenance represents a new challenge from standard vaccine delivery. Manufacturers also must ensure they can provide mRNA vaccines requiring -70º C temperature protection from the site of manufacture to their final destination.

There, the vaccines may be held in the original manufacturer’s shipper, which needs recharging after 10 days. Or they may be transferred to an ultra-low temperature freezer for storage or moved to a refrigerator if used within five days, in preparation for vaccination.

Esmon also identified gaps in the existing cold chain for vaccine distribution. The distribution process isn’t set up for large-scale transport of products that must be kept at ultra-low temperatures. Some manufacturers, he said, have responded by creating low-temperature storage containers for their vaccines that maintain a temperature of -70º C through transportation and up to 10 days with the aid of dry ice.

“We’re actively collaborating with FedEx, UPS, and large pharma manufacturers,” Esmon said. The logistics giants have established freezer farms enabling storage of large vaccine quantities. UPS’ farms are being built in Venlo, the Netherlands, and Louisville, KY. FedEx operates a Cold Chain Center in Memphis, TN, capable of storing frozen goods at -25º to -10º C. FedEx also added ten freezer facilities over the past three years, and plans to build more.

But very few pharmacies and clinics have equipment for storing and dispensing mRNA vaccines and other vaccines requiring very low temperature storage and for extended periods, Esmon said.

“These sites will need to have vaccination plans in place to manage these vaccines depending on the number of vaccines they receive and plan to distribute and in accordance with the parameters of the life of that vaccine,” Esmon said. “In many cases, because these vaccines are meant to be delivered quickly to patients and not stored, using the original shipping container or a 2º to 8º C refrigerator may be sufficient for the short time that vaccine is onsite prior to delivery to a patient.”

The post The Cold Truth about COVID-19 Vaccines appeared first on GEN - Genetic Engineering and Biotechnology News.

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

Trending